Drug companies kicked off the new year by announcing price hikes.
Allergan’s campaign for Vraylar portrays the highs and lows of bipolar disorder exactly as patients describe them.
The Swiss drugmaker, which reported an otherwise upbeat second quarter, allocated a substantial reserve to settle bribery charges stemming from the suit.
Allergan comes with a $63 billion price tag.
The drugmaker said that its decision not to pursue clinical trials on Alzheimer’s for Enbrel was based on science, not financial predictions.
Seven pharma executives were grilled on drug prices on Capitol Hill on Tuesday.